Anti-inflammatory effects of siponimod on astrocytes
Neuroscience Research, ISSN: 0168-0102, Vol: 184, Page: 38-46
2022
- 4Citations
- 11Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- CrossRef2
- Captures11
- Readers11
- 11
- Mentions1
- News Mentions1
- 1
Most Recent News
Studies from Yokohama City University Reveal New Findings on Life Science (Anti-inflammatory Effects of Siponimod On Astrocytes)
2022 NOV 04 (NewsRx) -- By a News Reporter-Staff News Editor at Japan Daily Report -- Investigators discuss new findings in Life Science. According to
Article Description
Siponimod, which is approved to treat active secondary progressive multiple sclerosis, acts as a functional antagonist of sphingosine-1-phosphate (S1P) receptor 1 (S1P 1 ) and an agonist of S1P 5. S1P 1 antagonization, which inhibits lymphocyte egress from lymphoid tissues and subsequent infiltration into the central nervous system (CNS), is considered the main therapeutic mechanism of siponimod. In addition, siponimod’s direct effects on CNS glial cells are another potential neuroprotective mechanism because siponimod can penetrate the blood–brain barrier and CNS glial cells express S1P receptors. However, it remains uncertain whether siponimod directly affects CNS glial cells. In this study, we investigated siponimod’s effects on astrocytes using mouse primary cultures. Siponimod suppressed nuclear factor kappa B activation and pro-inflammatory cytokine production. Using antagonists for S1P 1 and S1P 5, we found that siponimod partially exerts its anti-inflammatory effects via S1P 1, but not via S1P 5. Moreover, siponimod also inhibited histone deacetylase, suggesting that siponimod exerts broad anti-inflammatory effects via S1P 1 antagonization and histone deacetylase inhibition. Siponimod might suppress disease progression in multiple sclerosis in part via direct inhibition of astroglial CNS neuroinflammation.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0168010222002164; http://dx.doi.org/10.1016/j.neures.2022.08.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85135826878&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35940437; https://linkinghub.elsevier.com/retrieve/pii/S0168010222002164; https://dx.doi.org/10.1016/j.neures.2022.08.003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know